From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D058891:5-alpha Reductase Inhibitors; D000470:Alkaloids / Q000627:therapeutic use*; D000736:Androstenes / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use*; D005260:Female; D018120:Finasteride; D006801:Humans; D008297:Male; D016462:Mammaplasty; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D019736:Prostheses and Implants; D012828:Silicones; D014481:United States; D014486:United States Food and Drug Administration
D058891:5-alpha Reductase Inhibitors; D000470:Alkaloids; D000736:Androstenes; D000972:Antineoplastic Agents, Phytogenic; D001378:Azasteroids; D012828:Silicones; D018120:Finasteride; D017239:Paclitaxel